You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

BRAF inhibitor

Showing 26 - 50 of 7,849
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Melanoma Trial in United States (LGX818)

Completed
Has Results
  • Melanoma
  • Basking Ridge, New Jersey
  • +4 more
Jun 7, 2021

Thyroid Gland Anaplastic Carcinoma Trial in Saint Petersburg (Dabrafenib, Trametinib)

Recruiting
  • Thyroid Gland Anaplastic Carcinoma
  • Saint Petersburg, Russian Federation
    Saint-Petersburg State University (SPSU) N.I.Pirogov Clinic of H
Feb 3, 2021

Clinical Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage IIIA Cutaneous

Recruiting
  • Clinical Stage III Cutaneous Melanoma AJCC v8
  • +5 more
  • Jacksonville, Florida
  • +2 more
Oct 21, 2022

Advanced Malignant Tumor, BRAF Gene Mutation, Metastatic Malignant Tumor Trial in Houston (Crizotinib, Laboratory Biomarker

Completed
  • Advanced Malignant Neoplasm
  • +4 more
  • Houston, Texas
    M D Anderson Cancer Center
Jan 19, 2021

Cancer Trial in Worldwide (Dabrafenib, Trametinib)

Completed
Has Results
  • Cancer
  • Los Angeles, California
  • +49 more
Apr 1, 2022

Grade 1 Glioma, Mixed Glio-neuronal Tumors, Pleomorphic Xanthoastrocytoma Trial in Strasbourg (Trametinib, Vinblastine)

Recruiting
  • Grade 1 Glioma
  • +2 more
  • Strasbourg, France
    CHU Strasbourg - France
Jul 7, 2022

Melanoma (Skin), Melanoma Stage IIIb-IVM1a, Metastasis Skin Trial in Cincinnati (Talimogene laherparepvec (T-Vec), Dabrafenib

Withdrawn
  • Melanoma (Skin)
  • +4 more
  • Talimogene laherparepvec (T-Vec)
  • +2 more
  • Cincinnati, Ohio
    TriHealth Cancer Institute - Kenwood
Oct 14, 2020

Melanoma Trial in Jette (Dabrafenib, Trametinib, Hydroxychloroquine)

Recruiting
  • Melanoma
  • Jette, Brabant, Belgium
    UZ Brussel
Apr 27, 2021

Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Malignant Solid Tumor Trial in

Active, not recruiting
  • Clinical Stage III Cutaneous Melanoma AJCC v8
  • +4 more
  • Phoenix, Arizona
  • +48 more
Jan 3, 2023

NSCLC Trial in China, Taiwan (Encorafenib, Binimetinib)

Recruiting
  • Non-Small Cell Lung Cancer
  • Beijing, China
  • +35 more
Jun 29, 2022

Pediatric Recurrent/Refractory BRAFV600E-mutant Gliomas Trial in Canada, United States (Vemurafenib)

Active, not recruiting
  • Pediatric Recurrent/Refractory BRAFV600E-mutant Gliomas
  • Los Angeles, California
  • +20 more
Jan 4, 2023

Metastatic Colorectal Adenocarcinoma, Refractory Colorectal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v8 Trial (drug,

Not yet recruiting
  • Metastatic Colorectal Adenocarcinoma
  • +2 more
  • BET Bromodomain Inhibitor ZEN-3694
  • +6 more
  • (no location specified)
Oct 25, 2023

OPTImal PALliative Anti-epidermal Growth Factor Receptor

Active, not recruiting
  • Colorectal Cancer Metastatic
  • +5 more
  • Plasma circulating DNA analysis
  • Aarhus, Denmark
    Aarhus University Hospital
Feb 24, 2022

Non Small Cell Lung Cancer, KRAS Activating Mutation Trial in Worldwide (VS-6766, VS-6766 and Defactinib)

Recruiting
  • Non Small Cell Lung Cancer
  • KRAS Activating Mutation
  • avutometinib (VS-6766)
  • avutometinib (VS-6766) and Defactinib
  • Duarte, California
  • +44 more
Dec 22, 2022

BRAF Inhibitor Encorafenib And Cetuximab Real Life Investigation

Recruiting
  • Metastatic Colorectal Carcinoma
  • Aschaffenburg, Germany
  • +11 more
Dec 13, 2020

Recurrent Melanoma, Stage IIIB Melanoma, Stage IIIC Melanoma Trial in United States (trametinib, laboratory biomarker analysis,

Completed
Has Results
  • Recurrent Melanoma
  • +3 more
  • Washington, District of Columbia
  • +3 more
May 4, 2021

Malignant Melanoma Trial in Germany (Dabrafenib, Trametinib)

Terminated
  • Malignant Melanoma
  • Heidelberg, BW, Germany
  • +5 more
Oct 13, 2020

Biliary Tract Tumors, Gastric Cancer, Esophageal Squamous Cell Carcinoma Trial in Beijing (FGFR Inhibitor, IDH1 Inhibitor, HER2

Unknown status
  • Biliary Tract Neoplasms
  • +8 more
  • FGFR Inhibitor, IDH1 Inhibitor, HER2 Inhibitor, PARP Inhibitor, BRAF Inhibitor, MEK Inhibitor, ICIs, EGFR-TKIs, NTRK-TKI, and et. al.
  • Other Therapy
  • Beijing, Beijing, China
    Peking University Cancer Hospital
Oct 8, 2020

Advanced Solid Tumors, EGFR Positive NSCLC, Colorectal Carcinoma Trial in United States (TP-0903)

Active, not recruiting
  • Advanced Solid Tumors
  • +4 more
  • Phoenix, Arizona
  • +15 more
Apr 4, 2022

Metastatic Colorectal Cancer Trial in New York (AZD1775, Irinotecan)

Completed
  • Metastatic Colorectal Cancer
  • New York, New York
    Laura and Isaac Perlmutter Cancer Center
Oct 8, 2020

Advanced Cancer, Solid Tumor Trial in Houston (Vemurafenib, Everolimus, Temsirolimus)

Completed
  • Advanced Cancer
  • Solid Tumor
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
Jun 1, 2020

Recurrent Rectal Cancer, Stage IIA Rectal Cancer, Stage IIB Rectal Cancer Trial in United States (trametinib, fluorouracil,

Active, not recruiting
  • Recurrent Rectal Cancer
  • +6 more
  • Saint Louis, Missouri
  • +3 more
Feb 15, 2022

Metastatic Melanoma Trial in Copenhagen (Vemurafenib, Lymphodepleting chemo, TIL infusion)

Completed
Has Results
  • Metastatic Melanoma
  • Copenhagen, Herlev, Denmark
    Center for Cancer Immune Therapy, Dept. of Haematology/Oncology
Mar 10, 2020

Advanced Colorectal Cancer Trial in Hangzhou (Cetuximab Dabrafenib Tislelizumab)

Not yet recruiting
  • Advanced Colorectal Cancer
  • Cetuximab Dabrafenib Tislelizumab
  • Hangzhou, Zhejing, China
    Zhejiang Cancer Institute & Hospital
Jul 19, 2023

Melanoma Trial in Boston (MCS110, Dabrafenib, Trametinib)

Active, not recruiting
  • Melanoma
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Dec 14, 2022